VAViola Andresen

Viola Andresen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Viola Andresen has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Abdominal Cramping Pain

    by Stefan Müller-Lissner, Viola Andresen, Maura Corsetti, Luis Bustos Fernández, Sylvie Forestier, Fabio Pace, Miguel A. Valdovinos

    Functional abdominal cramping pain (FACP) is a common complaint, which may present either on its own or in association with a functional gastrointestinal disorder. It is likely caused by a variety of, probably partly unknown, etiologies. Effective management of FACP can be challenging owing to the lack of usable diagnostic tools and the availability of a diverse range of treatment approaches. Practical guidance for their selection and use is limited. The objective of this article is to present a working definition of FACP based on expert consensus, and to propose practical strategies for the diagnosis and management of this condition for physicians, pharmacists, and patients. A panel of experts on functional gastrointestinal disorders was convened to participate in workshop activities aimed at defining FACP and agreeing upon a recommended sequence of diagnostic criteria and management recommendations. The key principles forming the foundation of the definition of FACP and suggested management algorithms include the primacy of cramping pain as the distinguishing symptom; the importance of recognizing and acting upon alarm signals of potential structural disease; the recognition of known causes that might be addressed through lifestyle adjustment; and the central role of antispasmodics in the treatment of FACP. The proposed algorithm is intended to assist physicians in reaching a meaningful diagnostic endpoint based on patient-reported symptoms of FACP. We also discuss how this algorithm may be adapted for use by pharmacists and patients.


  • Reizdarmsyndrom – eine Krankheit

    by Viola Andresen, Peter Layer

    In der Vergangenheit war das Reizdarmsyndrom (RDS) häufig mit dem Stigma einer harmlosen psychosomatischen Befindlichkeitsstörung behaftet – heute gilt es bei wachsendem Verständnis der Pathophysiologie als „organische Erkrankung“. Auch werden zunehmend moderne, eher zielgerichtete Therapien für das RDS entwickelt. Dieser Beitrag fasst die aktuellen Kenntnisse zu Pathophysiologie, Diagnostik und Therapie dieser häufigsten Darmerkrankung zusammen.

  • Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real‑world setting – results from a German noninterventional study

    by Viola Andresen, Stephan Miehlke, Elmar Beck, Gwen Wiseman, Peter Layer

    Background Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist approved for the treatment of irritable bowel syndrome with constipation (IBS-C). This study assessed the efficacy and tolerability of linaclotide in IBS-C in routine clinical practice in Germany. Methods This was a 52-week, noninterventional study of linaclotide in patients aged ≥ 18 years with moderate to severe IBS-C. Severity of abdominal pain and bloating and frequency of bowel movements were assessed over 5 study visits. Treatment-related adverse events were recorded. Results The study enrolled 375 patients; the mean observation duration was 4.4 months. Linaclotide marketing was halted during the study period for economic reasons, accounting for low patient numbers and short observation duration. Linaclotide significantly reduced mean (standard deviation [SD]) scores between treatment start (visit 1) and study end (visit 5) for abdominal pain intensity (visit 1: 4.87 [2.63] vs. visit 5: 2.40 [2.20], p < 0.0001), mean [SD] bloating intensity (visit 1: 5.30 [2.70] vs. visit 5: 2.86 [2.34], p < 0.0001), and increased mean [SD] bowel movement frequency (visit 1: 2.71 [1.80] vs. 4.38 [1.86], p < 0.0001). Diarrhea, occurring in 5.1 % of patients, was the most common adverse event. Conclusion Linaclotide is effective in improving the major symptoms of IBS-C and demonstrates a favorable safety profile in the real-world environment of routine clinical practice. DRKS (www.drks.de/): DRKS00005088.


  • Open Access

    Medical Therapy of Constipation: Current Standards and Beyond

    by Viola Andresen, Peter Layer

    Chronic constipation is a very common medical problem with relevant impact on the patients' quality of life. Modern definitions recognize constipation as a polysymptomatic disorder, including various aspects of disturbed defecation. Current guidelines recommend a stepwise approach in the management of chronic constipation. Isolated or concomitant evacuation disorders should be identified and may need differential/additional treatment. Baseline measures include lifestyle components and bulking agents. The next step recommends treatment with conventional laxatives. In refractory patients, modern medical therapies, such as the prokinetic prucalopride or the secretagogues linalotide or lubiprostone, may be used effectively. For patients with opioid-induced constipation, the modern concept of peripherally acting µ-opioid antagonists has shown to successfully improve this increasing medical problem and even to potentially increase survival time in terminally ill patients on opioid therapy. Prolonged-released oral naloxone (in fixed combination with oxycodone), oral naloxegol or naldemedine, and subcutaneous methylnaltrexone have all demonstrated good efficacy and tolerability in the treatment of opioid-induced constipation. To adequately apply stepwise treatment algorithms, a simple tool to identify treatment failure may improve patient care.


  • Reizdarmsyndrom – eine Krankheit

    by Viola Andresen, Peter Layer

    The irritable bowel syndrome (IBS) counts among the most prevalent chronic diseases. Clinically, the IBS is characterized by abdominal symptoms combined with irregular defecation, which are not explained by routine diagnostic tests. IBS is often triggered by enteric bacterial infections, and its pathogenesis involves disturbed enteric, gut-brain, and cerebral mechanisms. Diagnostic work-up must aim to establish a positive IBS diagnosis, and to exclude serious underlying differential diagnoses (such as neoplasia, inflammatory bowel disease, celiac disease and others). On the other hand, it is important to avoid diagnostic “overkill” including repetitive testing. Successful treatment of IBS usually combines unspecific basic (nutritional, psychological, lifestyle etc.) measures with specific, symptom-oriented medical therapy. Therapeutic efficacy is greatly enhanced by ruling out worrying diagnostic uncertainties (reassurance), and by initiating positive patient guidance. In der Vergangenheit war das Reizdarmsyndrom (RDS) häufig mit dem Stigma einer harmlosen psychosomatischen Befindlichkeitsstörung behaftet – heute gilt es bei wachsendem Verständnis der Pathophysiologie als „organische Erkrankung“. Auch werden zunehmend moderne, eher zielgerichtete Therapien für das RDS entwickelt. Dieser Beitrag fasst die aktuellen Kenntnisse zu Pathophysiologie, Diagnostik und Therapie dieser häufigsten Darmerkrankung zusammen.


  • Die Bedeutung des Mikrobioms für die Adipositas

    by F. Bertram, D. Menge, V. Andresen


  • Nutrient Ingestion Lowers Colonic Sensory Thresholds in Patients with Severe Constipation

    by Jutta Keller, Sebastian Schulz, Viola Andresen, Peter Layer

  • Definitionen des Reizdarmsyndroms

    by V. Andresen, T. Frieling